Synergistic effect of inhibitors of MMPs and ROS-dependent modifications of contractile proteins on protection hearts subjected to oxidative stress

Current Pharmaceutical Design

Volumn 20, Issue 9, 2014, Pages 1345-1348

  Sawicki, Grzegorz ^a,b  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

^b WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

Contractile proteins; Ischemia reperfusion; Matrix metalloproteinase 2; Post translational modifications; Synergy

Indexed keywords

GELATINASE A; METALLOPROTEINASE INHIBITOR; MYOSIN LIGHT CHAIN; MYOSIN LIGHT CHAIN 1; MYOSIN LIGHT CHAIN 2; REACTIVE OXYGEN METABOLITE; TROPONIN I; UNCLASSIFIED DRUG; CARDIOTONIC AGENT; CONTRACTILE PROTEIN; MATRIX METALLOPROTEINASE;

ARTICLE; DRUG POTENTIATION; HEART PROTECTION; HUMAN; ISCHEMIC HEART DISEASE; NITROSYLATION; NONHUMAN; OXIDATIVE STRESS; OXYGEN CONSUMPTION; OXYGEN SUPPLY; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; REPERFUSION INJURY; ANIMAL; DRUG EFFECTS; METABOLISM; MYOCARDIAL ISCHEMIA; MYOCARDIAL REPERFUSION INJURY; PATHOPHYSIOLOGY; PHOSPHORYLATION; PHYSIOLOGY;

ANIMALS; CARDIOTONIC AGENTS; CONTRACTILE PROTEINS; DRUG SYNERGISM; HUMANS; MATRIX METALLOPROTEINASES; MYOCARDIAL ISCHEMIA; MYOCARDIAL REPERFUSION INJURY; OXIDATIVE STRESS; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; REACTIVE OXYGEN SPECIES;

EID: 84896337241     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/13816128113199990556     Document Type: Article

References (66)

1. Byrne JA, Grieve DJ, Cave AC, Shah AM. Oxidative stress and heart failure. Arch Mal Coeur Vaiss 2003; 96: 214-21.
2. Zhao ZQ, Vinten-Johansen J. Postconditioning: reduction of reperfusion-induced injury. Cardiovasc Res 2006; 70: 200-11.
3. Murdoch CE, Grieve DJ, Cave AC, Looi YH, Shah AM. NADPH oxidase and heart failure. Curr Opin Pharmacol 2006; 6: 148-53.
4. Murphy E, Steenbergen C. Mechanisms underlying acute protection from cardiac ischemia-reperfusion injury. Physiol Rev 2008; 88: 581-609.
5. Polewicz D, Cadete VJ, Doroszko A, et al. Ischemia induced peroxynitrite dependent modifications of cardiomyocyte MLC1 increases its degradation by MMP-2 leading to contractile dysfunction. J Cell Mol Med 2011; 15: 1136-47.
6. Stein AB, Bolli R, Guo Y, et al. The late phase of ischemic preconditioning induces a prosurvival genetic program that results in marked attenuation of apoptosis. J Mol Cell Cardiol 2007; 42: 1075-85.
7. Ferdinandy P, Schulz R. Nitric oxide, superoxide, and peroxynitrite in myocardial ischaemia-reperfusion injury and preconditioning. Br J Pharmacol 2003; 138: 532-43.
8. Schulz R, Triggle CR. Role of NO in vascular smooth muscle and cardiac muscle function. Trends Pharmacol Sci 1994; 15: 255-9.
9. Balligand JL, Cannon PJ. Nitric oxide synthases and cardiac muscle. Autocrine and paracrine influences. Arterioscler Thromb Vasc Biol 1997; 17: 1846-58.
10. Schulz R, Nava E, Moncada S. Induction and potential biological relevance of a Ca(2+)-independent nitric oxide synthase in the myocardium. Br J Pharmacol 1992; 105: 575-80.
11. Ziolo MT, Kohr MJ, Wang H. Nitric oxide signaling and the regulation of myocardial function. J Mol Cell Cardiol 2008; 45: 625-32.
12. Schulz R, Dodge KL, Lopaschuk GD, Clanachan AS. Peroxynitrite impairs cardiac contractile function by decreasing cardiac efficiency. Am J Physiol 1997; 272: H1212-9.
13. Schulz R, Panas DL, Catena R, Moncada S, Olley PM, Lopaschuk GD. The role of nitric oxide in cardiac depression induced by interleukin-1 beta and tumour necrosis factor-alpha. Br J Pharmacol 1995; 114: 27-34.
14. Panas D, Khadour FH, Szabo C, Schulz R. Proinflammatory cytokines depress cardiac efficiency by a nitric oxide-dependent mechanism. Am J Physiol 1998; 275: H1016-23.
15. Yasmin W, Strynadka KD, Schulz R. Generation of peroxynitrite contributes to ischemia-reperfusion injury in isolated rat hearts. Cardiovasc Res 1997; 33: 422-32.
16. Okamoto T, Akaike T, Nagano T, et al. Activation of human neutrophil procollagenase by nitrogen dioxide and peroxynitrite: a novel mechanism for procollagenase activation involving nitric oxide. Arch Biochem Biophys 1997; 342: 261-74.
17. Okamoto T, Akaike T, Sawa T, Miyamoto Y, van der Vliet A, Maeda H. Activation of matrix metalloproteinases by peroxynitriteinduced protein S-glutathiolation via disulfide S-oxide formation. J Biol Chem 2001; 276: 29596-602.
18. Gu Z, Kaul M, Yan B, et al. S-nitrosylation of matrix metalloproteinases: signaling pathway to neuronal cell death. Science 2002; 297: 1186-90.
19. Viappiani S, Nicolescu AC, Holt A, et al. Activation and modulation of 72kDa matrix metalloproteinase-2 by peroxynitrite and glutathione. Biochem Pharmacol 2009; 77: 826-34.
20. Cheung PY, Sawicki G, Salas E, Etches PC, Schulz R, Radomski MW. The mechanisms of platelet dysfunction during extracorporeal membrane oxygenation in critically ill neonates. Crit Care Med 2000; 28: 2584-90.
21. Fernandez-Patron C, Martinez-Cuesta MA, Salas E, et al. Differential regulation of platelet aggregation by matrix metalloproteinases-9 and-2. Thromb Haemost 1999; 82: 1730-5.
22. Sawicki G, Salas E, Murat J, Miszta-Lane H, Radomski MW. Release of gelatinase A during platelet activation mediates aggregation. Nature 1997; 386: 616-9.
23. Fernandez-Patron C, Radomski MW, Davidge ST. Vascular matrix metalloproteinase-2 cleaves big endothelin-1 yielding a novel vasoconstrictor. Circ Res 1999; 85: 906-11.
24. Fernandez-Patron C, Stewart KG, Zhang Y, Koivunen E, Radomski MW, Davidge ST. Vascular matrix metalloproteinase-2-dependent cleavage of calcitonin gene-related peptide promotes vasoconstriction. Circ Res 2000; 87: 670-6.
25. McQuibban GA, Gong JH, Tam EM, McCulloch CA, Clark-Lewis I, Overall CM. Inflammation dampened by gelatinase A cleavage of monocyte chemoattractant protein-3. Science 2000; 289: 1202-6.
26. Zhang K, McQuibban GA, Silva C, et al. HIV-induced metalloproteinase processing of the chemokine stromal cell derived factor-1 causes neurodegeneration. Nat Neurosci 2003; 6: 1064-71.
27. Rouet-Benzineb P, Buhler JM, Dreyfus P, et al. Altered balance between matrix gelatinases (MMP-2 and MMP-9) and their tissue inhibitors in human dilated cardiomyopathy: potential role of MMP-9 in myosin-heavy chain degradation. Eur J Heart Fail 1999; 1: 337-52.
28. Kwan JA, Schulze CJ, Wang W, et al. Matrix metalloproteinase-2 (MMP-2) is present in the nucleus of cardiac myocytes and is capable of cleaving poly (ADP-ribose) polymerase (PARP) in vitro. FASEB J 2004; 18: 690-2.
29. Hooper NM. Families of zinc metalloproteases. FEBS Lett 1994; 354: 1-6.
30. Handsley MM, Edwards DR. Metalloproteinases and their inhibitors in tumor angiogenesis. Int J Cancer 2005; 115: 849-60.
31. Tayebjee MH, Lip GY, MacFadyen RJ. Matrix metalloproteinases in coronary artery disease: clinical and therapeutic implications and pathological significance. Curr Med Chem 2005; 12: 917-25.
32. Nagase H, Visse R, Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res 2006; 69: 562-73.
33. Creemers EE, Cleutjens JP, Smits JF, Daemen MJ. Matrix metalloproteinase inhibition after myocardial infarction: a new approach to prevent heart failure? Circ Res 2001; 89: 201-10.
34. Dollery CM, McEwan JR, Henney AM. Matrix metalloproteinases and cardiovascular disease. Circ Res 1995; 77: 863-8.
35. Spinale FG, Coker ML, Bond BR, Zellner JL. Myocardial matrix degradation and metalloproteinase activation in the failing heart: a potential therapeutic target. Cardiovasc Res 2000; 46: 225-38.
36. Cheung PY, Sawicki G, Wozniak M, Wang W, Radomski MW, Schulz R. Matrix metalloproteinase-2 contributes to ischemiareperfusion injury in the heart. Circulation 2000; 101: 1833-9.
37. Wang W, Schulze CJ, Suarez-Pinzon WL, Dyck JR, Sawicki G, Schulz R. Intracellular action of matrix metalloproteinase-2 accounts for acute myocardial ischemia and reperfusion injury. Circulation 2002; 106: 1543-9.
38. Sawicki G, Leon H, Sawicka J, et al. Degradation of myosin light chain in isolated rat hearts subjected to ischemia-reperfusion injury: a new intracellular target for matrix metalloproteinase-2. Circulation 2005; 112: 544-52.
39. Schulze CJ, Wang W, Suarez-Pinzon WL, Sawicka J, Sawicki G, Schulz R. Imbalance between tissue inhibitor of metalloproteinase-4 and matrix metalloproteinases during acute myocardial [correction of myoctardial] ischemia-reperfusion injury. Circulation 2003; 107: 2487-92.
40. Doroszko A, Polewicz D, Cadete VJ, et al. Neonatal asphyxia induces the nitration of cardiac myosin light chain 2 that is associated with cardiac systolic dysfunction. Shock 2010; 34: 592-600.
41. Gao CQ, Sawicki G, Suarez-Pinzon WL, et al. Matrix metalloproteinase-2 mediates cytokine-induced myocardial contractile dysfunction. Cardiovasc Res 2003; 57: 426-33.
42. Wang W, Sawicki G, Schulz R. Peroxynitrite-induced myocardial injury is mediated through matrix metalloproteinase-2. Cardiovasc Res 2002; 53: 165-74.
43. Doroszko A, Polewicz D, Sawicka J, Richardson JS, Cheung PY, Sawicki G. Cardiac dysfunction in an animal model of neonatal asphyxia is associated with increased degradation of MLC1 by MMP-2. Basic Res Cardiol 2009; 104: 669-79.
44. Szczesna D. Regulatory light chains of striated muscle myosin. Structure, function and malfunction. Curr Drug Targets Cardiovasc Haematol Disord 2003; 3: 187-97.
45. Hernandez OM, Jones M, Guzman G, Szczesna-Cordary D. Myosin essential light chain in health and disease. Am J Physiol Heart Circ Physiol 2007; 292: H1643-54.
46. Lowey S, Waller GS, Trybus KM. Skeletal muscle myosin light chains are essential for physiological speeds of shortening. Nature 1993; 365: 454-6.
47. Moretti A, Weig HJ, Ott T, et al. Essential myosin light chain as a target for caspase-3 in failing myocardium. Proc Natl Acad Sci USA 2002; 99: 11860-5.
48. Morano I. Tuning the human heart molecular motors by myosin light chains. J Mol Med 1999; 77: 544-55.
49. Davis JS, Hassanzadeh S, Winitsky S, et al. The overall pattern of cardiac contraction depends on a spatial gradient of myosin regulatory light chain phosphorylation. Cell 2001; 107: 631-41.
50. Haase H, Dobbernack G, Tunnemann G, et al. Minigenes encoding N-terminal domains of human cardiac myosin light chain-1 improve heart function of transgenic rats. FASEB J 2006; 20: 865-73.
51. Goto T, Takase H, Toriyama T, et al. Circulating concentrations of cardiac proteins indicate the severity of congestive heart failure. Heart 2003; 89: 1303-7.
52. Hansen MS, Stanton EB, Gawad Y, et al. Relation of circulating cardiac myosin light chain 1 isoform in stable severe congestive heart failure to survival and treatment with flosequinan. Am J Cardiol 2002; 90: 969-73.
53. Van Eyk JE, Powers F, Law W, Larue C, Hodges RS, Solaro RJ. Breakdown and release of myofilament proteins during ischemia and ischemia/reperfusion in rat hearts: identification of degradation products and effects on the pCa-force relation. Circ Res 1998; 82: 261-71.
54. White MY, Cordwell SJ, McCarron HC, et al. Proteomics of ischemia/reperfusion injury in rabbit myocardium reveals alterations to proteins of essential functional systems. Proteomics 2005; 5: 1395-410.
55. Kobayashi T, Solaro RJ. Calcium, thin filaments, and the integrative biology of cardiac contractility. Annu Rev Physiol 2005; 67: 39-67.
56. Walker JW. Protein kinase C, troponin I and heart failure: overexpressed, hyperphosphorylated and underappreciated? J Mol Cell Cardiol 2006; 40: 446-50.
57. Akiyama K, Akopian G, Jinadasa P, et al. Myocardial infarction and regulatory myosin light chain. J Mol Cell Cardiol 1997; 29: 2641-52.
58. White MY, Cordwell SJ, McCarron HC, Tchen AS, Hambly BD, Jeremy RW. Modifications of myosin-regulatory light chain correlate with function of stunned myocardium. J Mol Cell Cardiol 2003; 35: 833-40.
59. Arrell DK, Neverova I, Fraser H, Marban E, Van Eyk JE. Proteomic analysis of pharmacologically preconditioned cardiomyocytes reveals novel phosphorylation of myosin light chain 1. Circ Res 2001; 89: 480-7.
60. Kanski J, Behring A, Pelling J, Schoneich C. Proteomic identification of 3-nitrotyrosine-containing rat cardiac proteins: effects of biological aging. Am J Physiol Heart Circ Physiol 2005; 288: H371-81.
61. Kanski J, Hong SJ, Schoneich C. Proteomic analysis of protein nitration in aging skeletal muscle and identification of nitrotyrosine-containing sequences in vivo by nanoelectrospray ionization tandem mass spectrometry. J Biol Chem 2005; 280: 24261-6.
62. van der Loo B, Labugger R, Skepper JN, et al. Enhanced peroxynitrite formation is associated with vascular aging. J Exp Med 2000; 192: 1731-44.
63. Fert-Bober J, Leon H, Sawicka J, et al. Inhibiting matrix metalloproteinase-2 reduces protein release into coronary effluent from isolated rat hearts during ischemia-reperfusion. Basic Res Cardiol 2008; 103: 431-43.
64. Ali MAM, Cho WJ, Hudson B, Kassiri Z, Granzier H, Schulz R. Titin is a Target of Matrix Metalloproteinase-2 Implications in Myocardial Ischemia/Reperfusion Injury. Circulation 2010; 122: 2039-U106.
65. Force T, Kuida K, Namchuk M, Parang K, Kyriakis JM. Inhibitors of protein kinase signaling pathways: emerging therapies for cardiovascular disease. Circulation 2004; 109: 1196-205.
66. Cadete VJJ, Sawicka J, Jaswal J, et al. Ischemia/reperfusioninduced myosin light chain 1 phosphorylation increases its degradation by matrix metalloproteinase-2. FEBS J 2012; 279: 2444-54.